- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01491997
Mind-Body Medicine and Ulcerative Colitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Statistical Analysis. The investigator will use the biopsychomarkers identified as the highest prediction value to determine the relative accuracy to predict response to the Mindful Intervention (i.e., disease outcome). For response to the mindful intervention, the investigator will use the use the combination of markers to study whether they correctly predict the response to the intervention. The investigator will study the accuracy of the markers using area under the curve (AUC) summary index for ROC curves.181 If the classification accuracy of the markers is high then the area under the curve will be close to 1. If the predictive accuracy of the combined set of markers were poor then the (AUC) will be close to 0.5.
Power Estimates UC disease flare-up was quite common in this sample, occurring in well over half of subjects in the samples collected in the discovery phase. The power analyses, assuming α = 0.05 for all tests indicated that for models involving analyses of correlational data, there will be sufficient power at even small effect sizes for the smallest possible sample with full data across all data points and virtually all variables. For the most conservative estimate, the investigator base their calculations on having 50 participants with data with full integrity. With an effect size of r = 0.15 and n = 50, power is 80 or greater to detect effect sizes of r = 0.20. Effect sizes below this threshold would likely not be clinically significant or substantively interpretable, as they would explain less than 2% in the variance of the dependent variable. Thus, most effect sizes that would be reasonably and substantially interpretable will have good power. Each factor that is suspected of varying between groups can be examined with the chi-square test based on 1 degrees of freedom, by setting it invariant in one model and then allowing it to be freely estimated in the other. Such a chi-square test provides a power of 0.80 with effect size difference of 0.15.
For binary categorical measures, such as responsiveness to MSRB, the investigator conducted separate power analyses.
The power for adjusted analyses of primary predictors of interest will be evaluated as a function of the risk of outcome when all ancillary variables are set to their mean value, the predictor is set to the mean value, and proportion of variance in predictor explained by the ancillary variables, and the odds ratio of outcome variable from increasing the predictor by an amount equal to one of its standard deviation. The range in probabilities of outcome variables can be anywhere from 20% for less likely events and 50% for more likely events, the investigator will provide power calculations over a wide range of probabilities. The investigator believe that the amount of variation of our typical model ranges from about 20% to 50%. The table (below) represents the minimum odds ratio than can be detected with 80% power, which indicate good power for expected outcome.
Proportions R2 =.20 R2=.50 0.10 1.64 1.87 0.20 1.46 1.63 0.30 1.39 1.53 0.40 1.35 1.48 0.50 1.32 1.43
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- You have been diagnosed with moderately severe Ulcerative Colitis at the time of your last flare up
- You experienced at least one flare-up within the last year
- Either no IBD medication or have been on a stable dose of oral 5-ASA products (i.e. Mesalamine, Sulfasalazine, or Colazol) for at least 3 weeks, immunomodulators (Imuran, 6MP, Methotrexate)for at least 3 months and biologics (TNF antibody) for at least 6 months prior to enrollment
- If on maintenance 5-ASA products or immunomodulators and dose changes during the study, participant agrees to remain on that dose for the study duration
- ACTIVE UC PATIENTS: If on Prednisone the dose must not be more than 20mg/day; you can be weaned off Prednisone by 5mg/day weekly to 10mg/day weekly to 2.5mg/day weekly
Exclusion Criteria:
- Other forms of colitis, such as Clostridium Difficile Colitis or Indeterminate Colitis
- Current use of oral steroids within the last 30 days, topical agents (i.e. steroids or 5-ASA) within the last 14 days
- History of colon resection
- Antibiotic use within the last 14 days
- WOMEN: Cannot be pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Mind Body Medicine Course 1
The subject of each course is Mind/Body medicine.
One course is learning about the mind and the body through experiences.
The other is learning about the mind and the body through experiences.
Both courses will follow the same format, meeting once every week, for a total of 8 weeks, for roughly 2 hours per class.
You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time.
Weekly sessions will be run by a teacher and will include other participants in the class. .
You will also be given homework assignments that are intended to reinforce what you learn in the program.
The assignments will require up to 45 minutes, 6 days/week.
Following the 6th class, and before the 7th class, there is a voluntary ½ day Saturday program.
Participation in this program is optional.
You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
|
The subject of the course is Mind/Body medicine.
This course is learning about the mind and the body through experiences.
The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class.
You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time.
Weekly sessions will be run by a teacher and will include other participants in the class.
You will also be given homework assignments that are intended to reinforce what you learn in the program.
The assignments will require up to 45 minutes, 6 days/week.
Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program.
Participation in this program is optional.
You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
|
ACTIVE_COMPARATOR: Mind/Body Medicine Course 2
The subject of the course is Mind/Body medicine.
This course is learning about the mind and the body through lectures.
The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class.
You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time.
Weekly sessions will be run by a teacher and will include other participants in the class.
You will also be given homework assignments that are intended to reinforce what you learn in the program.
The assignments will require up to 45 minutes, 6 days/week.
Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program.
Participation in this program is optional.
You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
|
The subject of the course is Mind/Body medicine.
This course is learning about the mind and the body through lectures.
The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class.
You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time.
Weekly sessions will be run by a teacher and will include other participants in the class.
You will also be given homework assignments that are intended to reinforce what you learn in the program.
The assignments will require up to 45 minutes, 6 days/week.
Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program.
Participation in this program is optional.
You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biopsychomarkers
Time Frame: 4 years
|
Develop a set of biopsychomarkers to (a) identify characteristics that predict UC patient's response to Mind/Body Medicine courses and (b) establish an objective set of markers that demonstrate the impact of Mind/Body Medicine courses on well-being and UC disease state.
|
4 years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AT11-003 - 1 R01 AT007143-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Palatin Technologies, IncRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Assistance Publique - Hôpitaux de ParisMRSU 938 - Research Center of Saint AntoineNot yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Protagonist Therapeutics, Inc.CompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereUnited States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
-
Theravance BiopharmaCompletedActive Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy SubjectsUnited States
-
Altheus Therapeutics, Inc.UnknownUlcerative Colitis | Left-sided Ulcerative Colitis | Distal Ulcerative ColitisUnited States
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...CompletedIntensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-TARGET (In-TARGET)ULCERATIVE COLITISFrance, Belgium
-
Xijing Hospital of Digestive DiseasesNot yet recruitingUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Severe | Rectal UlcerChina
Clinical Trials on Mind/Body Medicine Course 1
-
The Center for Mind-Body MedicineSilicon Valley Community FoundationCompleted
-
Mercy Medical CenterCompleted
-
The Center for Mind-Body MedicineSimon Family FoundationEnrolling by invitation
-
Universität Duisburg-EssenRobert Bosch Medical CenterRecruiting
-
Universität Duisburg-EssenCompletedQuality of Life | Breast Cancer | Chemotherapy | Acupuncture | Mind-Body-MedicineGermany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGlioblastoma | Malignant Glioma | WHO Grade III Glioma | Metastatic Malignant Neoplasm in the Brain | Low Grade Glioma | PartnerUnited States
-
Universität Duisburg-EssenCompleted
-
Beth Israel Deaconess Medical CenterRecruiting
-
Beth Israel Deaconess Medical CenterCompletedChronic Pain | Chronic Pain SyndromeUnited States
-
University of AlbertaCompletedPrimary Biliary CirrhosisCanada